Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma
Journal of Cancer Research & Clinical Oncology, 11/10/09

Yao X et al. – Results of this study suggest that HMGB1 protein is a valuable marker for progression of CRC patients. High HMGB1 expression is associated with poor overall survival in patients with CRC.

Methods

Investigated HMGB1 expression and its prognostic significance in CRC by performing immunohistochemical analysis, using a total of 192 paraffin-embedded archival CRC samples
Disruption of endogenous HMGB1 protein through a siRNA knockdown technique performed to investigate possible role of HMGB1 in process of tumor invasion and metastasis

Results

Overexpression of HMGB1 shown in 55.7% cases
Statistical analysis showed HMGB1 expression positively correlated with tumor invasion (P = 0.048), lymph node metastasis , distant metastasis , and Duke’s stage of CRC patients
Patients with higher HMGB1 expression had shorter overall survival time, whereas patients with lower level of HMGB1 had better survival
Multivariate analysis suggested HMGB1 expression might be independent prognostic indicator for survival of patients with CRC
Disruption of endogenous HMGB1 protein through a siRNA knockdown technique shown to suppress substantially invasion ability of SW620 cells

<< Previous
The location of lymphangiogenesis is an independent prognostic...

Next >>
Neoadjuvant chemotherapy with a combination of docetaxel,...